Answers are grounded in this paper and cite their sources.
The emergence of carbapenem-resistant Acinetobacter baumannii (CRAB) has become a serious global health concern. In the United States, nearly half of A. baumannii strains isolated from patients with healthcare-associated infections are resistant to carbapenems [1]. Mortality in patients with CRAB infections is high (approximately 33%) and treatment options are limited [2]. The cost of treating CRAB is considerable and makes up part of the estimated $2.2 billion spent in the United States annually on antibiotic-resistant infections [3]. Despite a growing body of research including the use of synergistic combinations from two or three different classes of antibiotics, the optimal treatment of CRAB remains uncertain. Indeed, a recent study that included over 300 cases of CRAB found combination therapy was not superior to monotherapy [4]. The topic of antibiotic therapy for CRAB has been comprehensively reviewed [5]. Shin and Park also recently described the complex mechanisms of antimicrobial resistance in A. baumannii [6].Therefore, this article describes some emerging nonpharmacologic approaches for CRAB including fecal microbiota transplantation (FMT), vaccines, bacteriophage, and monoclonal antibodies (MAbs) as well as recommends areas where further research is needed to tackle this ‘formidable foe.’ Many patients admitted to intensive care units (ICUs) harbor CRAB in their intestinal flora, especially those with prior exposure to carbapenems [7]. Thus, there is growing interest in using FMT as a method of decolonization. FMT involves the administration of screened, healthy donor stool into a patient’s gastrointestinal tract, either into the colon by enema or colonoscopy, or into the upper small intestine by nasojejunal tube or swallowed capsules. FMT has proven to be very effective for treating recalcitrant Clostridium difficile infections (CDIs). In one such case, a patient who was chronically colonized with several multidrug resistant (MDR) organisms including CRAB and suffered recurrent infections from them developed CDI. The patient underwent FMT, which successfully resolved the CDI and resulted in a reduction in post-FMT MDR infections [8]. This case and others provides a proof-ofconcept for using FMT to eradicate CRAB colonization of the lower gastrointestinal tract. Recently, Leung and colleagues used whole metagenome sequencing data from 8 FMT donor–recipient pairs to identify 37 and 95 AMR genes acquired by or removed from FMT recipients, respectively [9]. Specifically, they observed the loss of genes belonging to the extended-spectrum β-lactamase (ESBL), glycopeptide, and quinolone antimicrobial classes along with the polymyxin resistance gene PmrC-F. Although no large, randomized controlled trials have been conducted, preliminary data for using FMT as a decolonization strategy for patients harboring CRAB in the gastrointestinal tract appear promising. However, the cost of FMT may be a limitation, especially if payers refuse to cover the procedure. Vaccination against MDR pathogens like CRAB is an attractive concept because of the potential for less antibiotic exposure and the generation of herd immunity in patients most susceptible to CRAB infections, such as the immunocompromised or those in ICUs. Several potential A. baumannii antigens have been identified including outer membrane vesicles (OMVs), outer membrane protein A (OmpA), auto-transporter (Ata), biofilm-associated protein (Bap), K1 capsular polysaccharide, and Poly-N-acetyl-β-(1–6)-glucosamine (PNAG) [10]. Currently no vaccines for CRAB have progressed beyond phase I clinical development. One candidate vaccine that uses Gram negative bacteria-derived OMVs, which are highly immunogenic and induce a robust response against bacterial infection, was found to protect mice from a lethal challenge with a clinically isolated A. baumannii strain [11]. One obstacle for vaccines against CRAB is the sequence variability of the antigens and their absence in circulating CRAB strains may result in poor cross-protective efficacy against strains that cause hospital-acquired infections (HAIs). This is due to mutations that can occur because of selective immunological pressure, leading to down-regulation of the target antigens [10]. Thus, identifying highly conserved antigens from CRAB strains that cause HAIs needs to be a research priority. Another challenge is identifying a patient population to include in a clinical trial of vaccine efficacy that has a high short-term risk for developing a CRAB infection. Bacteriophages (aka phages) are viruses that invade and kill bacteria by lysis but do not harm human cells. First discovered
No takes yet. Share an insight, caveat, or question.
Richard Watkins (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: